The US biopharma industry needs to come forward with proposals to effectively address the lack of price negotiation for prescription drugs covered by Medicare and won’t get away with talking points about preserving innovation and access any more, HHS Secretary Alex Azar warned at policy gathering sponsored by the American Enterprise Institute and the USC-Brookings Schaeffer Initiative for Health Policy May 16.
Azar focused on two areas of Medicare drug coverage where the Trump Administration believes there is no price negotiation, or...






